The Global Diaries
The data through the reason 1 and reason 2 trials will guidance approaching regulatory filings so that twice-annually lenacapavir for PrEP, if accredited, may be licensed for various populations and communities worldwide who will be most in need of added HIV prevention options.
America seeks to imp